5-MeO-MPMI

5-MeO-MPMI
Legal status
Legal status	DE: NpSG (Industrial and scientific use only); UK: Class A;
Identifiers
	IUPAC name 5-Methoxy-3-{[(2R)-1-methylpyrrolidin-2-yl]methyl}-1H-indole;
CAS Number	143321-57-7 ;
PubChem CID	9881324;
ChemSpider	8057000 ;
UNII	N29TFW7VRV;
ChEMBL	ChEMBL137485 ;
CompTox Dashboard (EPA)	DTXSID401027538 ;
Chemical and physical data
Formula	C15H20N2O
Molar mass	244.338 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CN1CCC[C@@H]1CC2=CNC3=C2C=C(C=C3)OC;
	InChI InChI=1S/C15H20N2O/c1-17-7-3-4-12(17)8-11-10-16-15-6-5-13(18-2)9-14(11)15/h5-6,9-10,12,16H,3-4,7-8H2,1-2H3/t12-/m1/s1 ; Key:MKEGUJPBCIXABO-GFCCVEGCSA-N ;
	(what is this?) (verify)

5-MeO-MPMI (also known as 5-Methoxy-N-methyl-(α,N-trimethylene)tryptamine) is a tryptamine derivative that is a psychedelic drug. It was first developed by the team led by JE Macor in 1992, and subsequently investigated by the team led by David Nichols from Purdue University in the late 1990s. This compound produces psychedelic-appropriate responding in animal tests with a similar potency to the amphetamine-derived psychedelic DOI, and has two enantiomers, with only the (R)-enantiomer being active.